Atria delivered a strong Q3, with adjusted EBIT 35% above LSEG Data & Analytics consensus.
Limited estimate revisions Growth appears more capital-light than history suggests Trading at '25e E...
Catalyst to grow 94% in Q3'24e EBIT revised down by 1.
Redeye provides a research update following the Q4 report recently published by Newbury.
Hyresintäkterna sjönk något till 847 mkr, främst drivet av tidigare avyttrade fastigheter.
Redeye provides a note about CLS’s decision to concentrate fully on its neurosurgery business.
Q3 with healthy 7% organic growth despite headwinds Growth and cost improvement yields 300bp margin ...
Organic growth of 31%, +6pp vs. ABGSCe Significant EBITDA improvement Likely positive consensus esti...
EBIT SEK 40m vs. ABG SEK 47m — higher costs, lower volumes Q4 likely weaker driven by maintenance Co...
Atria reported Q3 adjusted EBIT of EUR 25.8m, 35% (EUR 6.
Redeye comments on Active Biotech's Q3 report. During the quarter, Active Biotech reported laquinimo...
Redeye anticipates the Lifecare division to maintain its solid performance in Q3 2024, though weaker...
Redeye’s first comments follow this morning’s Q3 report from Tagmaster.
During October, Cibus has acquired three grocery stores in Finland for EUR 14.
Raute reports Q3 results on Oct 31. The company upgraded guidance as in our view especially Wood Pro...
Administer announced yesterday that it will lower its revenue guidance to EUR 74-76m, while narrowin...
LapWall releases its Q3 business review on the 29th of October.
Top-line estimate cuts partly mitigated by lower rates Outgrowing the sector on high share of floati...
Q3 EBITDA +5-6% and Net Profit +12-21% Guidance unchanged as expected Checkmark on Q3, while we awai...
Q3 report Friday, 25 October, 07:00 CET '24e-'26e EBITA up 0-2%; 7% CAGR '23-'26e 13-10x EBITA '24e-...